4:06 PM ET
8-K
Other 8-K Filing
Karyopharm Therapeutics Other 8-K Filing
Karyopharm Therapeutics issued 20,000 shares of a newly created Series A Convertible Perpetual Preferred Stock to satisfy $20.0 million in fees owed under a forbearance agreement with its lenders. The preferred stock is convertible into common stock at $1.62 per share, though initial conversions are capped at 19.99% of outstanding shares pending stockholder approval.